Perspectives
"Hereditary AngioEdema (HAE) is a rare, severely debilitating genetic disease that has been diagnosed in approximately 10,000 people in the US and EU. Yet significant furor surrounds the recent developments in HAE treatment options. Why is there so much interest and increasing competition for a niche indication for which an approved product is unlikely to achieve more than $300-400m in worldwide peak sales? " ... Read more
22 Jul 2008 | From the latest Perspectives entry by Subita Srimal, Hereditary AngioEdema: Targeting Niche Indications Fetches A Premium
Research Library . Recent Updates
| 18 Nov 2008 | UTHR-Update on FREEDOM-C Failure » |
|---|---|
| 18 Nov 2008 | Healthcare Reforms In Japan & Emerging Opportunities For Generic Companies » |
| 14 Nov 2008 | Rigel Syk Update » |
| 14 Nov 2008 | ARQL - Proof Now Will Lie in the Pudding » |
| 14 Nov 2008 | Bio Marin Kuvan Update » |
